Skip to main content
SpringerLink
Log in

Scleroderma in Pigmented Skin Populations

  • Chapter
  • First Online:
Pigmented Ethnic Skin and Imported Dermatoses

  • 984 Accesses

Abstract

Scleroderma, or more accurately systemic sclerosis (SSc), is a multi-organ systemic disease involving inflammation, vascular destruction, and disrepair with collagen deposition and fibrosis. Early recognition leading to timely management positively impacts survival and disease progression.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Oyoo O, Moots RJ, Ganda B. Stepping into the state of rheumatology in East Africa. Rheumatology (Oxford). 2012;51:1345–6.

    Article  Google Scholar 

  2. Chifflot H, Fautrel B, Sordet C, et al. Incidence and prevalence of systemic sclerosis: a systematic literature review. J Semin Arthritis Rheum. 2008;37:223–35.

    Article  Google Scholar 

  3. Dia D, Dieng MT, Sy TN, et al. Systemic scleroderma: 92 cases in Dakar. Dakar Med. 2003;48:82–6.

    PubMed  CAS  Google Scholar 

  4. Adelowo OO, Oguntona S. Scleroderma (systemic sclerosis) among Nigerians. Clin Rheumatol. 2009;28:1121–5.

    Article  CAS  PubMed  Google Scholar 

  5. Mijiyawa M, Amanga K, Oniankitan OI, et al. Connective tissue diseases in the hospital outpatient service in Lomé (Togo). Rev Med Interne. 1999;20:13–7.

    Article  CAS  PubMed  Google Scholar 

  6. Pitche P, Amanga Y, Koumouvi K, et al. Scleroderma in a hospital setting in Togo. Med Trop. 1998;58:65–8.

    CAS  Google Scholar 

  7. Tager RE, Tikly M. Clinical and laboratory manifestations of systemic sclerosis (scleroderma) in Black South Africans. Rheumatology (Oxford). 1999;38:397–400.

    Article  CAS  Google Scholar 

  8. Steen VD, Oddis CV, Conte CG, Janoski J, Casterline GZ, Medsger TA Jr. Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963-1982. Arthritis Rheum. 1997;40:441–5. PMID: 90829319.

    Article  CAS  PubMed  Google Scholar 

  9. Steen V, Domsic RT, Lucas M, Fertig N, Medsger TA Jr. A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. Arthritis Rheum. 2012;64:2986–94. https://doi.org/10.1002/art.34482. PMID: 225766201.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Reveille JD, Durban E, Goldstein R, Moreda R, Arnett FC. Racial differences in the frequencies of scleroderma-related autoantibodies. Arthritis Rheum. 1992;35:216–8. PMID: 1734910.

    Article  CAS  PubMed  Google Scholar 

  11. Laing TJ, Gillespie BW, Toth MB, et al. Racial differences in scleroderma among women in Michigan. Arthritis Rheum. 1997;40:734–42.

    Article  CAS  PubMed  Google Scholar 

  12. Beall AD, Nietert PJ, Taylor MH, et al. Ethnic disparities among patients with pulmonary hypertension associated with systemic sclerosis. J Rheumatol. 2007;34:1277–82.

    PubMed  Google Scholar 

  13. Mayes MD. Scleroderma epidemiology. Rheum Dis Clin N Am. 1996;22:751–64.

    Article  CAS  Google Scholar 

  14. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003;48:2246–55.

    Article  PubMed  Google Scholar 

  15. Medsger TA Jr, Masi AT. The epidemiology of systemic sclerosis (scleroderma) among male U.S. veterans. J Chronic Dis. 1978;31:73–85.

    Article  PubMed  Google Scholar 

  16. Wang J, Assassi S, Guo G, et al. Clinical and serological features of systemic sclerosis in a Chinese cohort. Clin Rheumatol. 2013;32:617–21.

    Article  CAS  PubMed  Google Scholar 

  17. McNeilage LJ, Youngchaiyud U, Whittingham S. Racial differences in antinuclear antibody patterns and clinical manifestations of scleroderma. Arthritis Rheum. 1989;32:54–60.

    Article  CAS  PubMed  Google Scholar 

  18. Pakunpanya K, Verasertniyom O, Vanichapuntu M, et al. Incidence and clinical correlation of anticentromere antibody in Thai patients. S Clin Rheumatol. 2006;25:325–8.

    Article  Google Scholar 

  19. Krishnamurthy V, Porkodi R, Ramakrishnan S, et al. Progressive systemic sclerosis in south India. J Assoc Physicians India. 1991;39:254–7.

    PubMed  CAS  Google Scholar 

  20. Kumar A, Malaviya AN, Tiwari SC, et al. Clinical and laboratory profile of systemic sclerosis in northern India. J Assoc Physicians India. 1990;38:765–8.

    PubMed  CAS  Google Scholar 

  21. Pradhan V, Rajadhyaksha A, Nadkar M, et al. Clinical and autoimmune profile of scleroderma patients from Western India. Int J Rheumatol. 2014;2014:983781.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Sharma VK, Trilokraj T, Khaitan B, et al. Profile of systemic sclerosis in a tertiary care center in North India. Indian J Dermatol Venereol Leprol. 2006;72:416–20.

    Article  PubMed  Google Scholar 

  23. Eason RJ, Tan PL, Gow PJ. Progressive systemic sclerosis in Auckland: a ten year review with emphasis on prognostic features. Aust NZ J Med. 1981;11:657–62.

    Article  CAS  Google Scholar 

  24. Le Guern V, Mahr A, Mouthon L, et al. Prevalence of systemic sclerosis in a French multi-ethnic county. Rheumatology (Oxford). 2004;43:1129–37.

    Article  Google Scholar 

  25. Kuwana M, Okano Y, Kaburaki J, et al. Racial differences in the distribution of systemic sclerosis-related serum antinuclear antibodies. Arthritis Rheum. 1994;37:902–6.

    Article  CAS  PubMed  Google Scholar 

  26. Nietert PJ, Silver RM, Mitchell HC, et al. Demographic and clinical factors associated with in-hospital death among patients with systemic sclerosis. J Rheumatol. 2005;32:1888–92.

    PubMed  Google Scholar 

  27. Rocha LF, Luppino Assad AP, Marangoni RG, et al. Systemic sclerosis and silica exposure: a rare association in a large Brazilian cohort. Rheumatol Int. 2016;36:697–702.

    Article  CAS  PubMed  Google Scholar 

  28. Bernatsky S, Smargiassi A, Johnson M, et al. Fine particulate air pollution, nitrogen dioxide, and systemic autoimmune rheumatic disease in Calgary, Alberta. Environ Res. 2015;140:474–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Jimenez SA, Diaz A, Khalili K. Retroviruses and the pathogenesis of systemic sclerosis. Int Rev Immunol. 1995;12:159–75.

    Article  CAS  PubMed  Google Scholar 

  30. Neidhart M, Kuchen S, Distler O, et al. Increased serum levels of antibodies against human cytomegalovirus and prevalence of autoantibodies in systemic sclerosis. Arthritis Rheum. 1999;42:389–92.

    Article  CAS  PubMed  Google Scholar 

  31. Marie I, Gehanno JF. Environmental risk factors of systemic sclerosis. Semin Immunopathol. 2015;37:463–73.

    Article  CAS  PubMed  Google Scholar 

  32. Maître A, Hours M, Bonneterre V, et al. Systemic sclerosis and occupational risk factors: role of solvents and cleaning products. J Rheumatol. 2004;31:2395–401.

    PubMed  Google Scholar 

  33. Cowie RL, Dansey RD. Features of systemic sclerosis (scleroderma) in South African goldminers. S Afr Med J. 1990;77:400–2.

    PubMed  CAS  Google Scholar 

  34. Del Papa N, Quirici N, Scavullo C, et al. Antiendothelial cell antibodies induce apoptosis of bone marrow endothelial progenitors in systemic sclerosis. J Rheumatol. 2010;37:2053–63.

    Article  PubMed  Google Scholar 

  35. Riemekasten G, Philippe A, Näther M, et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis. 2011;70:530–6.

    Article  CAS  PubMed  Google Scholar 

  36. Baroni SS, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med. 2006;354:2667–76.

    Article  CAS  PubMed  Google Scholar 

  37. Riemekasten G, Cabral-Marques O. Antibodies against angiotensin II type 1 receptor (AT1R) and endothelin receptor type A (ETAR) in systemic sclerosis (SSc)-response. Autoimmun Rev. 2016;15:935.

    Article  PubMed  Google Scholar 

  38. Distler JH, Gay S, Distler O. Angiogenesis and vasculogenesis in systemic sclerosis. Rheumatology (Oxford). 2006;45(Suppl 3):iii26–7. Erratum in: Rheumatology (Oxford) 2008;47:234–35.

    CAS  Google Scholar 

  39. Tsou PS, Rabquer BJ, Ohara RA, et al. Scleroderma dermal microvascular endothelial cells exhibit defective response to pro-angiogenic chemokines. Rheumatology (Oxford). 2016;55:745–54.

    Article  CAS  Google Scholar 

  40. Bogatkevich GS, Ludwicka-Bradley A, Highland KB, et al. Impairment of the antifibrotic effect of hepatocyte growth factor in lung fibroblasts from African Americans: possible role in systemic sclerosis. Arthritis Rheum. 2007;56:2432–42.

    Article  CAS  PubMed  Google Scholar 

  41. Bogatkevich GS, Highland KB, Akter T, et al. The PPARγ agonist rosiglitazone is antifibrotic for scleroderma lung fibroblasts: mechanisms of action and differential racial effects. Pulm Med. 2012;2012:545172.

    Article  CAS  PubMed  Google Scholar 

  42. Silver RM, Bogatkevich G, Tourkina E, et al. Racial differences between blacks and whites with systemic sclerosis. Curr Opin Rheumatol. 2012;24:642–8.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72:1747–55.

    Article  PubMed  Google Scholar 

  44. Maricq HR, Weinrich MC. Diagnosis of Raynaud’s phenomenon assisted by color charts. J Rheumatol. 1988;15:454–9.

    PubMed  CAS  Google Scholar 

  45. Gelber AC, Manno RL, Shah AA, et al. Race and association with disease manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature. Medicine (Baltimore). 2013;92:191–205.

    Article  Google Scholar 

  46. Nusbaum JS, Gordon JK, Steen VD. African American race associated with body image dissatisfaction among patients with systemic sclerosis. Clin Exp Rheumatol. 2016;34 Suppl 100:70–3.

    PubMed  Google Scholar 

  47. Cannick L, Douglas G, Crater S, et al. Nodular scleroderma: case report and literature review. J Rheumatol. 2003;30:2500–2.

    PubMed  Google Scholar 

  48. Ramos PS, Silver RM, Feghali-Bostwick CA. Genetics of systemic sclerosis: recent advances. Curr Opin Rheumatol. 2015;27:521–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Black HR, Quallich H, Gareleck CB. Racial differences in serum creatine kinase levels. Am J Med. 1986;81:479–87.

    Article  CAS  PubMed  Google Scholar 

  50. Spechler SJ, Jain SK, Tendler DA, et al. Racial differences in the frequency of symptoms and complications of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2002;16:1795–80.

    Article  CAS  PubMed  Google Scholar 

  51. Segal I. The gastro-oesophageal reflux disease complex in sub-Saharan Africa. Eur J Cancer Prev. 2001;10:209–12.

    Article  CAS  PubMed  Google Scholar 

  52. Sonnenberg A. Effects of environment and lifestyle on gastroesophageal reflux disease. Dig Dis. 2011;29:229–34.

    Article  PubMed  Google Scholar 

  53. Nietert PJ, Mitchell HC, Bolster MB, et al. Racial variation in clinical and immunological manifestations of systemic sclerosis. J Rheumatol. 2006;33:263–8.

    PubMed  Google Scholar 

  54. McNearney TA, Reveille JD, Fischbach M, et al. Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum. 2007;57:318–26.

    Article  PubMed  Google Scholar 

  55. Greidinger EL, Flaherty KT, White B, et al. African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest. 1998 Sep;114:801–7.

    Article  CAS  PubMed  Google Scholar 

  56. Aggarwal R, Lucas M, Fertig N, et al. Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum. 2009;60:1112–8.

    Article  PubMed  Google Scholar 

  57. Shapiro LS, Saketkoo L, Farrell JF, et al. Development of a “Renal Crisis Prevention Card” as an educational tool aimed at improving outcomes in high-risk patients with systemic sclerosis. Abstract 2716 ACR/ARHP Annual Meeting, November 2014; Boston, MA.

    Google Scholar 

Download references

Acknowledgment

The authors wish to gratefully acknowledge the editorial and research contributions of Roberta Lukasiewicz, Heather Sickler, and Tammy Kelly to the development and writing of this chapter.

Author information

Authors and Affiliations

  1. Division of Rheumatology, Albany Medical College, Albany, NY, USA

    Lee Shapiro M.D.

  2. Clinical Immunology, Allergy and Rheumatology, Pulmonary Diseases, Critical Care and Environmental Medicine, New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, Tulane University School of Medicine, Tulane Lung Center, New Orleans, LA, USA

    Lesley Ann Saketkoo M.D., M.P.H.

  3. Department of Medicine, Georgetown University Medical Center, Pasquerilla Healthcare Center, Washington, DC, USA

    Virginia D. Steen M.D.

Authors
  1. Lee Shapiro M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lesley Ann Saketkoo M.D., M.P.H.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Virginia D. Steen M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Free University of Berlin, Medical School Charité, Berlin, Germany

    Constantin E. Orfanos

  2. Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane, Dessau, Saxony-Anhalt, Germany

    Christos C. Zouboulis

  3. Department of Dermatology and Venereology, HELIOS Klinikum Krefeld, Krefeld, Nordrhein-Westfalen, Germany

    Chalid Assaf

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Shapiro, L., Saketkoo, L.A., Steen, V.D. (2018). Scleroderma in Pigmented Skin Populations. In: Orfanos, C., Zouboulis, C., Assaf, C. (eds) Pigmented Ethnic Skin and Imported Dermatoses. Springer, Cham. https://doi.org/10.1007/978-3-319-69422-1_42

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-69422-1_42

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-69421-4

  • Online ISBN: 978-3-319-69422-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation